3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Genitourinary
2
CNS
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Classical hematology
1
Breast
1
Conditions
Sarcoma
4
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
11
Gemcitabine
10
Doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Nivolumab
8
Ibandronic Acid
8
pazopanib
7
Radiosurgery
6
Magnetic Resonance Spectroscopy
6
Imatinib Mesylate
6
Biopsy
6
Bevacizumab
6
Irinotecan
5
regorafenib
4
Zoledronic Acid
4
Ipilimumab
4
Ifosfamide
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
sargramostim
3
conatumumab
3
cemiplimab
3
Sunitinib
3
Radiation
3
Paclitaxel
3
Leucovorin
3
Cryosurgery
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
entrectinib
×
Sarcoma
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA